We provide you with 20 years of free, institutional-grade data for INBX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of INBX. Explore the full financial landscape of INBX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Inhibrx, Inc(NASDAQ:INBX) 
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarc...
Website: http://www.inhibrx.com
Founded: 2010
Full Time Employees: 75
CEO: Mark P. Lappe
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about INBX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.